company background image
A207

Samsung BiologicsLtd KOSE:A207940 Stock Report

Last Price

₩793.00k

Market Cap

₩56.4t

7D

0.6%

1Y

-11.0%

Updated

18 May, 2022

Data

Company Financials +
A207940 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance5/6
Financial Health5/6
Dividends0/6

A207940 Stock Overview

Samsung Biologics Co., Ltd. engages in the contract manufacturing organization business for biopharmaceuticals products.

Samsung BiologicsLtd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Samsung BiologicsLtd
Historical stock prices
Current Share Price₩793,000.00
52 Week High₩1,047,000.00
52 Week Low₩693,000.00
Beta0.83
1 Month Change-3.88%
3 Month Change4.76%
1 Year Change-11.00%
3 Year Change165.22%
5 Year Change288.72%
Change since IPO450.69%

Recent News & Updates

Shareholder Returns

A207940KR Life SciencesKR Market
7D0.6%-3.0%0.9%
1Y-11.0%-16.4%-15.0%

Return vs Industry: A207940 exceeded the KR Life Sciences industry which returned -16.4% over the past year.

Return vs Market: A207940 exceeded the KR Market which returned -15% over the past year.

Price Volatility

Is A207940's price volatile compared to industry and market?
A207940 volatility
A207940 Average Weekly Movement3.3%
Life Sciences Industry Average Movement6.6%
Market Average Movement5.6%
10% most volatile stocks in KR Market10.3%
10% least volatile stocks in KR Market3.2%

Stable Share Price: A207940 is less volatile than 75% of KR stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: A207940's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20113,247John Chongbo Rimhttps://samsungbiologics.com

Samsung Biologics Co., Ltd. engages in the contract manufacturing organization business for biopharmaceuticals products. It is involved in the provision of contract development organization services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services.

Samsung BiologicsLtd Fundamentals Summary

How do Samsung BiologicsLtd's earnings and revenue compare to its market cap?
A207940 fundamental statistics
Market Cap₩56.44t
Earnings (TTM)₩393.59b
Revenue (TTM)₩1.57t

143.4x

P/E Ratio

36.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A207940 income statement (TTM)
Revenue₩1.57t
Cost of Revenue₩844.66b
Gross Profit₩723.35b
Other Expenses₩329.76b
Earnings₩393.59b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)5.53k
Gross Margin46.13%
Net Profit Margin25.10%
Debt/Equity Ratio25.5%

How did A207940 perform over the long term?

See historical performance and comparison

Valuation

Is Samsung BiologicsLtd undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


143.4x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: A207940 (₩793000) is trading above our estimate of fair value (₩448185.31)

Significantly Below Fair Value: A207940 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: A207940 is poor value based on its PE Ratio (143.4x) compared to the KR Life Sciences industry average (22.2x).

PE vs Market: A207940 is poor value based on its PE Ratio (143.4x) compared to the KR market (14.5x).


Price to Earnings Growth Ratio

PEG Ratio: A207940 is poor value based on its PEG Ratio (9.3x)


Price to Book Ratio

PB vs Industry: A207940 is overvalued based on its PB Ratio (11.3x) compared to the KR Life Sciences industry average (2.9x).


Future Growth

How is Samsung BiologicsLtd forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


15.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: A207940's forecast earnings growth (15.4% per year) is above the savings rate (3.5%).

Earnings vs Market: A207940's earnings (15.4% per year) are forecast to grow faster than the KR market (15% per year).

High Growth Earnings: A207940's earnings are forecast to grow, but not significantly.

Revenue vs Market: A207940's revenue (14.7% per year) is forecast to grow faster than the KR market (9.6% per year).

High Growth Revenue: A207940's revenue (14.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: A207940's Return on Equity is forecast to be low in 3 years time (8.4%).


Past Performance

How has Samsung BiologicsLtd performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


56.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A207940 has high quality earnings.

Growing Profit Margin: A207940's current net profit margins (25.1%) are higher than last year (20.7%).


Past Earnings Growth Analysis

Earnings Trend: A207940 has become profitable over the past 5 years, growing earnings by 56% per year.

Accelerating Growth: A207940's earnings growth over the past year (63.3%) exceeds its 5-year average (56% per year).

Earnings vs Industry: A207940 earnings growth over the past year (63.3%) exceeded the Life Sciences industry 18.1%.


Return on Equity

High ROE: A207940's Return on Equity (7.9%) is considered low.


Financial Health

How is Samsung BiologicsLtd's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: A207940's short term assets (₩2,823.2B) exceed its short term liabilities (₩1,107.3B).

Long Term Liabilities: A207940's short term assets (₩2,823.2B) exceed its long term liabilities (₩1,871.6B).


Debt to Equity History and Analysis

Debt Level: A207940 has more cash than its total debt.

Reducing Debt: A207940's debt to equity ratio has increased from 20.6% to 25.5% over the past 5 years.

Debt Coverage: A207940's debt is well covered by operating cash flow (35.7%).

Interest Coverage: A207940's interest payments on its debt are well covered by EBIT (106.4x coverage).


Balance Sheet


Dividend

What is Samsung BiologicsLtd current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A207940's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A207940's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A207940's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A207940's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A207940 has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

John Chongbo Rim (60 yo)

1.42yrs

Tenure

₩995,000,000

Compensation

Mr. John Chongbo Rim has been President of Samsung Biologics Co.,Ltd. since December 17, 2020. Mr. Rim has been Chief Executive Officer of Samsung Biologics Co.,Ltd.since December 8, 2020 and its Director...


CEO Compensation Analysis

Compensation vs Market: John Chongbo's total compensation ($USD784.24K) is below average for companies of similar size in the KR market ($USD1.29M).

Compensation vs Earnings: John Chongbo's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: A207940's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: A207940's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.6%.


Top Shareholders

Company Information

Samsung Biologics Co.,Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Samsung Biologics Co.,Ltd.
  • Ticker: A207940
  • Exchange: KOSE
  • Founded: 2011
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₩56.441t
  • Shares outstanding: 71.17m
  • Website: https://samsungbiologics.com

Number of Employees


Location

  • Samsung Biologics Co.,Ltd.
  • 300, Songdo Bio-daero
  • Yeonsu-gu
  • Incheon
  • 21987
  • South Korea

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/18 00:00
End of Day Share Price2022/05/18 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.